跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Recardio, Inc.

首页临床试验发起方与机构Recardio, Inc.

Recardio, Inc.

ACTIVE

加利福尼亚州旧金山县, California, 美国www.recardio.euPrivate11–50 名员工成立于: 2011-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

9

7 进行中

药物批准

0

批准总数

监管机构

0

监管机构数

成立时间

2011

概览

试验阶段分布

阶段

试验数

占比

1 期

6

66.7%

2 期

2

22.2%

3 期

1

11.1%

试验状态分布

进行中（未招募）

6

66.7%

已完成

2

22.2%

尚未招募

1

11.1%

相关临床试验

该机构主办的试验（9）

Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction

Sep 20234100 名受试者

A clinical study in humans of a new drug (dutogliptin) with an existing drug (filgrastim) for use after a heart attack.

进行中（未招募）

Feb 2019140 名受试者

Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction

Dec 201849 名受试者

A clinical study in humans of a new drug (dutogliptin) with an existing drug (filgrastim) for use after a heart attack.

进行中（未招募）

Jul 2018140 名受试者

A clinical study in humans of a new drug (dutogliptin) with an existing drug (filgrastim) for use after a heart attack.

进行中（未招募）

May 2018140 名受试者

A clinical study in humans of a new drug (dutogliptin) with an existing drug (filgrastim) for use after a heart attack.

进行中（未招募）

Apr 2018140 名受试者

A clinical study in humans of a new drug (dutogliptin) with an existing drug (filgrastim) for use after a heart attack.

进行中（未招募）

Apr 2018140 名受试者

A clinical study in humans of a new drug (dutogliptin) with an existing drug (filgrastim) for use after a heart attack.

进行中（未招募）

Mar 2018140 名受试者

第 1 页，共 2 页

药物批准

暂无批准数据

资讯

Kancera Advances Cardiovascular Drug Pipeline with Recardio Partnership and FDA Engagement

- Kancera AB has partnered with US biotech Recardio Inc. to create a cardiovascular disease-focused specialty care company, with Recardio licensing candidate drugs KAND567 and KAND145. - The company expects FDA pre-IND feedback for its planned phase IIb FRACTIVE study of KAND567 in acute myocardial infarction by the end of Q2 2025. - Top-line results from the ongoing KANDOVA phase Ib/IIa study evaluating KAND567 plus carboplatin in ovarian cancer are expected in Q3 2025. - Kancera plans to rebrand as Novakand Pharma in September 2025, reflecting its strategic focus on cardiovascular therapeutics.

本页目录

概览
相关临床试验9
药物批准
资讯1

返回机构列表